V-Bio Ventures

The concept of a "biological missile" isn't new, but our portfolio company atbtherapeutics is perfecting it. Their technology allows them to bioengineer the antibody and payload as a single, highly stable molecule and the platform is versatile enough to incorporate diverse payloads, such as peptides or enzymes, tailored to the specific disease. This new BioVox interview by Amy LeBlanc with Bertrand Magy and Max Houry explains how atbtherapeutics is using a plant-based platform to engineer atbodies-fusion proteins that combine the specificity of antibodies with unique payloads. It takes a special team to turn a plant into a cancer-fighting machine: Bertrand Magy, Max Houry, Mark Throsby, Torsten Dreier. 🌱 📰 Read the full article here: https://lnkd.in/eq-uqMRp #Oncology #Immunotherapy #AntibodyTherapeutics #ADC #Biotech #LifeSciences #Pharma #Innovation #Innovation #MolecularFarming

We are delighted to announce Shelley Margetson, Managing Partner at V-Bio Ventures, as the final panellist joining our oversubscribed Annual Investor Breakfast during London Life Sciences Week! Shelley brings a perspective shaped by years of steering biotech companies through pivotal inflection points. Her experience guiding organisations through public markets and leading strategic transactions, including IPOs, funding rounds and international partnerships, brings valuable insight into how companies navigate growth, structure exits and align stakeholders in evolving market conditions. This blend of financial acuity and hands-on leadership will add an important dimension to the discussion. Our 2025 theme, “Reinventing the VC Wheel: Adapting Capital Models to a New Era of Innovation,” will examine how investors and industry strategics are adapting their approaches in response to an increasingly complex funding environment. We look forward to Shelley’s contribution to what promises to be a sharp and forward-looking conversation. #CavenaghHealth #LondonLifeSciencesWeek #LifeSciences #LLSW25 #VentureCapital #VC #BiotechInvestment #Innovation #HealthcareFinance

👏 Proud of our portfolio company Agomab for positive topline Phase 2a data in fibrostenosing Crohn’s: STENOVA met its primary safety endpoint in 103 patients after 12 weeks, with gut‑restricted PK and encouraging signals on SES‑CD and MRE. Phase 2b planning next—congrats to the team and investigators! Full press release: https://lnkd.in/eqPdix4d

👁️ Thrilled to see our portfolio company Coave Therapeutics advancing a lead gene therapy for retinal vascular diseases with a first-in-class suprachoroidal AAV vector—expanding genetic medicine from rare to prevalent eye conditions. 👏 Congrats to the Coave team on this milestone and the continued innovation of the ALIGATER platform.

🧠 Thrilled to celebrate a major milestone from our portfolio: Muna Therapeutics has dosed the first subjects in its Phase 1 study of MNA-001, a novel oral TREM2 agonist. By boosting microglia’s protective functions against the pathology that drives cognitive decline, this strategy is a shift toward enhancing brain resilience rather than simply clearing pathology in early Alzheimer’s disease. We look forward to the Phase 1 data expected in summer 2026. 👏 Congratulations to Rita Balice-Gordon, Anders Mørkeberg Hinsby, Niels Plath, Jakob Busch-Petersen, David Howe and the entire team on this important step forward for patients and families affected by Alzheimer's disease. Read the full press release here: https://lnkd.in/e_mhHijp #Alzheimers #AlzheimersDisease #Neurodegeneration #Biotech #ClinicalTrial

📣 Augustine Therapeutics is hiring! We are seeking a highly experienced and motivated Senior Director, Translational Pharmacology to join our team in Leuven to drive the advancement of small molecule therapies from concept to clinical testing. For more information, please go to: https://lnkd.in/eEiMY5Hu ➡️ To apply, click here: https://lnkd.in/eccpH77E

Great to see Andy Parker, CEO of our portfolio company Step Pharma share how the team has translated CTPS1 biology into a clear and ambitious development strategy for dencatistat in from lymphoma, solid tumours and essential thrombocythaemia!

Thrilled to see our portfolio company BIODOL THERAPEUTICS strengthen its leadership team with the appointments of Marie Gourlay-Chu as Chief Medical Officer and Loïc LAPLANCHE as Chief Operating Officer, as the company advances first-in-class, non-opioid pain candidate BDT272 through clinical development. https://lnkd.in/e6sJQbZW

We often talk about strong science, experienced teams, smart strategy, and solid funding. But there’s another critical, often overlooked factor: how teams disagree. In his latest piece for BioVox, our managing partner Willem Broekaert explores how the way leaders handle internal debate—balancing conflict and consensus—can make or break biotech ventures. From destructive conflict to excessive harmony, and finally to the sweet spot of constructive controversy, his analysis of what distinguishes high-performing teams from the rest is a must-read for founders, biotech executives, and investors alike: https://lnkd.in/egJ8h-KW

Great news from V-Bio Ventures portfolio company Step Pharma! Step Pharma has appointed Karen S. as Chief Medical Officer. Karen brings over 25 years of experience across development, regulatory affairs, and medical leadership in pharma and biotech and will strengthen the company’s clinical development efforts for its first-in-class CTPS1 inhibitor across oncology and hematology indications. Welcome to Karen for joining this exciting journey! https://lnkd.in/es7huenE #Biotech #DrugDevelopment #oncology